Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pay-for-delay

- PMLiVE

Von der Leyen elected new European Commission president

Pledges green deal and universal healthcare for 500m citizens

Teva Pharma logo

US states sue generic firms over ‘inflated’ prices

Companies accused of “multi-billion dollar fraud" and conspiracy

- PMLiVE

Lundbeck snaps up Abide Therapeutics for $400m

Also acquires its lead drug for Tourette’s syndrome

- PMLiVE

FDA panel backs J&J’s new-class antidepressant

Set to be first novel antidepressant approved since Prozac in 1987

- PMLiVE

Industry aghast as EU Parliament backs biosimilar rule change

The change could come into effect in 2021

Generic Differentiation

Even in the cost-led market for generics, differentiated business models evolve

Innovation in merger control and the impact on the pharmaceutical sector

Is focusing on pipeline products enough to assess regulatory risks?

- PMLiVE

Pharma sees European generics export plan as anti-innovation

EFPIA condemns plans - but European Commission says changes would create jobs in Europe

- PMLiVE

Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug

Foliglurax is currently in phase II testing for LID, muscle stiffness and ‘freezing’

- PMLiVE

Lundbeck and Otsuka start phase III for Rexulti in bipolar

Drug is also in phase II trial to treat PTSD patients

- PMLiVE

Teva poaches Lundbeck’s Schultz as new CEO

Shares in Lundbeck fall as two senior posts become vacant

Life lessons

The recent problems of the generics sector have lessons for research-based companies too

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links